Evolving molecularly targeted therapies for advanced-stage thyroid cancers

KC Bible, M Ryder - Nature Reviews Clinical Oncology, 2016 - nature.com
Increased understanding of disease-specific molecular targets of therapy has led to the
regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of …
被引用次数：95 相关文章

Evolving molecularly targeted therapies for advanced-stage thyroid cancers

KC Bible, M Ryder - Nature Reviews Clinical Oncology, 2016 - go.gale.com
Increased understanding of disease-specific molecular targets of therapy has led to the
regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of …

Evolving molecularly targeted therapies for advanced-stage thyroid cancers

KC Bible, M Ryder - Nature Reviews Clinical Oncology, 2016 - mayoclinic.elsevierpure.com
Increased understanding of disease-specific molecular targets of therapy has led to the
regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of …

Evolving molecularly targeted therapies for advanced-stage thyroid cancers

KC Bible, M Ryder - Nature reviews. Clinical oncology, 2016 - pubmed.ncbi.nlm.nih.gov
Increased understanding of disease-specific molecular targets of therapy has led to the
regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of …

Evolving molecularly targeted therapies for advanced-stage thyroid cancers.

KC Bible, M Ryder - Nature reviews. Clinical Oncology, 2016 - europepmc.org
Increased understanding of disease-specific molecular targets of therapy has led to the
regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of …